ARGX vs NBIX
Argenx SE and Neurocrine Biosciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ARGX | NBIX |
|---|---|---|
| Revenue | $4.2B | $2.9B |
| Net income | $1.3B | $478.6M |
| Gross margin | 89.1% | 98.2% |
| Net margin | 31.1% | 16.7% |
| Return on equity | 20.2% | 16.4% |
| Diluted EPS | $19.57 | $4.67 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $679.0M | $748.7M |
| Equity | · | $3.3B |
| Net debt / equity | · | · |
| Current ratio | 5.23× | 3.39× |
| Revenue CAGR 5y | 151.5% | 22.3% |
| Profit CAGR 5y | · | 3.3% |
ARGX bills 1.5× the revenue of NBIX, and keeps more of each dollar of revenue as profit (31.1% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ARGX | NBIX |
|---|---|---|
| FY2025 | $4.2B | $2.9B |
| FY2024 | $2.2B | $2.4B |
| FY2023 | $1.2B | $1.9B |
| FY2022 | $400.7M | $1.5B |
| FY2021 | $497.3M | $1.1B |
| FY2020 | $41.2M | $1.0B |
| FY2019 | $78.5M | $788.1M |
| FY2018 | · | $451.2M |
| FY2017 | · | $161.6M |
| FY2016 | · | $15.0M |
Bottom line
| Fiscal year | ARGX | NBIX |
|---|---|---|
| FY2025 | $1.3B | $478.6M |
| FY2024 | $833.0M | $341.3M |
| FY2023 | $-295.1M | $249.7M |
| FY2022 | $-709.6M | $154.5M |
| FY2021 | $-408.3M | $89.6M |
| FY2020 | $-608.5M | $407.3M |
| FY2019 | $-181.2M | $37.0M |
| FY2018 | · | $21.1M |
| FY2017 | · | $-142.5M |
| FY2016 | · | $-141.1M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$1,290,816,000 | ARGX |
| FY2024 | −$169,417,000 | NBIX |
| FY2023 | −$696,317,000 | NBIX |
| FY2022 | −$1,087,980,000 | NBIX |
| FY2021 | −$636,223,000 | NBIX |
| FY2020 | −$1,004,657,000 | NBIX |
| FY2019 | −$709,638,000 | NBIX |
The higher-revenue side has changed between ARGX and NBIX over this period. The gap has widened since the earliest year compared.
7 of 17 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +14.4 pp | ARGX |
| FY2024 | +23.6 pp | ARGX |
| FY2023 | −38.0 pp | NBIX |
| FY2022 | −187.5 pp | NBIX |
| FY2021 | −90.0 pp | NBIX |
| FY2019 | −235.6 pp | NBIX |
| FY2018 | −314.9 pp | NBIX |
| FY2017 | +11.1 pp | ARGX |
| FY2016 | +795.3 pp | ARGX |
| FY2015 | +226.4 pp | ARGX |
The higher net margin has changed hands between ARGX and NBIX over this period.
10 of 14 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's net margin has been more volatile than ARGX's over the 10 comparable fiscal years — 299.7 percentage points of standard deviation against 111.0.
10 of 14 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ARGX and NBIX over these 10 fiscal years — ARGX led in 5 and NBIX in 5.
10 of 14 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's return on equity has been more volatile than ARGX's over the 11 comparable fiscal years — 25.1 percentage points of standard deviation against 20.5.
11 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ARGX and NBIX over these 11 fiscal years — ARGX led in 3 and NBIX in 8.
11 of 17 comparable fiscal years — a year missing data on either side is not counted.